Here are the 10-Q quarterly reports from T3 Defense Inc. (DFNS) in our archive since June 2025, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 10-Q covers the quarterly report filed between annual reports, so if you follow DFNS and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full DFNS filings page.
T3 Defense Inc. (DFNS) reported its first meaningful defense revenues while posting a very large accounting loss for the six months ended June 30, 2026. Revenue was $7.6 million versus none a year earlier, generating gross profit of $1.4 million, but a net loss attributable to stockholders of $109.6 million, driven mainly by a $102.2 million non‑cash increase in stock purchase warrant liabilities.
Total assets were $316.0 million, including $175.9 million of SPAC trust assets and $99.0 million of goodwill, against total liabilities of $159.8 million and a stockholders’ deficit of $19.7 million. Operating cash outflow was $9.9 million, partially funded by $15.4 million of net financing inflows, including a $10 million private placement and draws under an equity line of credit. Management acknowledges significant liquidity pressure but concludes that existing cash, the ELOC, cash‑generating Israeli subsidiaries, and cost‑reduction plans collectively alleviate substantial doubt about continuing as a going concern.
T3 Defense Inc. reported first‑quarter 2026 revenue of $3.7 million, reflecting new defense operations at Rimon, ITS and Tiltan. Despite this, the company posted a net loss attributable to stockholders of $27.1 million, driven largely by a $26.6 million loss from the change in fair value of stock purchase warrant liabilities.
Total assets rose to $315.5 million, including $100.2 million of goodwill from recent acquisitions such as Star 26, Nimbus and ITS, while stockholders’ equity improved to $42.5 million from a deficit a year earlier. Operating loss was $3.8 million, and cash used in operating activities was $4.9 million, partly offset by $12.5 million of financing inflows from a private placement, loans and ELOC share sales.
Management acknowledges negative working capital of about $69 million but concludes that existing cash, an equity line of credit and cash‑positive subsidiaries alleviate substantial doubt about continuing as a going concern. Subsequent events include a Nasdaq minimum bid‑price deficiency notice, a sale of Zorronet for BiomX stock and a note, debt‑for‑equity exchanges, and a share swap with VisionWave.